Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.

ABSTRACT:

Introduction

Glioblastoma (GBM) has a survival rate of around 2 years with aggressive current standard of care. While other tumors have responded favorably to trials combining immunotherapy and chemotherapy, GBM remains uniformly deadly with minimal increases in overall survival. GBM differ from others due to being isolated behind the blood brain barrier, increased heterogeneity and mutational burden, and immunosuppression from the brain environment and tumor itself.

Methods

We have reviewed clinical and preclinical studies investigating how different doses (dose intense (DI) and metronomic) and timing of immunotherapy following TMZ treatment can eradicate tumor cells, alter tumor mutational burden, and change immune cells.

Results

Recent clinical trials with standard

SUBMITTER: Hotchkiss KM 

PROVIDER: S-EPMC9833842 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature